| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.067 | 0.4 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |